Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | GSTA1 | P08263 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL638047 | 0.83 | MAPT (0.63) | MAPTPOLBKDM4EGLADGAT1 | |
| SCHEMBL30375142 | 0.83 | MAPT (0.63) | MAPTPOLBKDM4EGLADGAT1 | |
| SCHEMBL3908082 | 0.80 | MAPT (0.58) | MAPTPOLBKDM4EGLADGAT1 | |
| SCHEMBL30089256 | 0.80 | MAPT (0.58) | MAPTPOLBKDM4EGLADGAT1 | |
| SCHEMBL2821586 | 0.77 | MAPT (0.73) | MAPTPOLBKDM4EGLAPLAU | |
| SCHEMBL13291389 | 0.75 | CES2 (0.42) | MAPTPOLBDGAT1HPGDALDH1A1 | |
| SCHEMBL28594338 | 0.75 | MAPT (0.83) | MAPTPOLBKDM4EGLAPLAU | |
| SCHEMBL28171560 | 0.75 | KDM4E (0.73) | MAPTPOLBKDM4EGLAPLAU | |
| SCHEMBL4464312 | 0.74 | DGAT1 (0.70) | MAPTPOLBKDM4EGLADGAT1 | |
| SCHEMBL26738 | 0.74 | MAPT (1.00) | MAPTPOLBKDM4EGLAPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728142-B2 | 3-methanesulfonylquinolines as GABAB enhancers | HOFFMANN-LA ROCHE INC. (US) | 2010-06-01 | — | — | US | claimed |
| EP-1893560-A2 | 3-METHANESULFONYLQUINOLINES AS GABA-B ENHANCERS | F. Hoffmann-Roche AG (CH) | 2008-03-05 | — | — | EP | claimed |
| WO-2006128802-A2 | 3-METHANESULFONYLQUINOLINES AS GABA-B ENHANCERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-07 | — | — | WO | claimed |
| US-20060276469-A1 | such as 3-Methanesulfonyl-2-methyl-4-phenyl-6-trifluoromethoxy-quinoline for treatment of CNS disorders such as anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy | HOFFMANN-LA ROCHE INC. | 2006-12-07 | — | — | US | claimed |
| US-7728142-B2 | 3-methanesulfonylquinolines as GABAB enhancers | HOFFMANN-LA ROCHE INC. (US) | 2010-06-01 | — | — | US | disclosed |
| EP-1893560-A2 | 3-METHANESULFONYLQUINOLINES AS GABA-B ENHANCERS | F. Hoffmann-Roche AG (CH) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006128802-A2 | 3-METHANESULFONYLQUINOLINES AS GABA-B ENHANCERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-07 | — | — | WO | disclosed |
| US-20060276469-A1 | such as 3-Methanesulfonyl-2-methyl-4-phenyl-6-trifluoromethoxy-quinoline for treatment of CNS disorders such as anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy | HOFFMANN-LA ROCHE INC. | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276469-A1 | such as 3-Methanesulfonyl-2-methyl-4-phenyl-6-trifluoromethoxy-quinoline for treatment of CNS disorders such as anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy | GABBR1, GABRR3, GABRR2 | MAPT 1272/4885POLB 2677/4885KDM4E 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.